- to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with with type 2 diabetes mellitus who are at high risk for these events

Regular health monitoring Baseline testing before starting: Complete blood count (CBC) Comprehensive metabolic panel (liver, kidney function) Fasting glucose and insulin IGF-1 levels Thyroid panel (TSH, T3, T4) Follow-up testing: Every 3-6 months while using peptides Immediately if concerning symptoms Compare to baseline What to monitor: Blood sugar regulation Liver and kidney function Thyroid function IGF-1 levels (shouldn't be excessively elevated) Lipid profile When to stop: Any concerning blood markers Persistent side effects Signs of organ stress Unusual symptoms Cycling and breaks For growth hormone peptides: CJC-1295 + Ipamorelin: Can use 3-6+ months continuously GHRP-6: Cycle 8-12 weeks, break 4-8 weeks Hexarelin: Cycle 4 weeks, break 4+ weeks (not recommended for most) For healing peptides: BPC-157: Can use continuously TB-500: Can use continuously or cycle 8-16 weeks on, 4-8 weeks off GHK-Cu: Can use continuously Why breaks matter: Prevent receptor desensitization Allow natural hormone production to recover Reduce long-term risk Reset tolerance See peptide cycle planning guide and can you cycle different peptides

Heres what most people dont realize: glutathione has over 180,000 published studies on PubMed
Who is more likely to get GLP-1 sulfur burps
The primary endpoint was major adverse cardiovascular events (often called MACE), a combined measure of: Cardiovascular death Nonfatal heart attack Nonfatal stroke Over a median follow-up of about 3.5 years, semaglutide reduced the relative risk of these events by about 20% compared with placebo